Please login to the form below

Not currently logged in
Email:
Password:

Prexton

This page shows the latest Prexton news and features for those working in and with pharma, biotech and healthcare.

Lundbeck signs $1.1bn deal for Prexton and Parkinson’s drug

Lundbeck signs $1.1bn deal for Prexton and Parkinson’s drug

Lundbeck bolstered its R&D pipeline ahead of the weekend with a 900m ($1.1bn) deal to acquire Prexton Therapeutics and its mid-stage Parkinson’s disease (PD) candidate foliglurax. ... Prexton was set up in 2012 as a spin-out from Merck Serono’s R&D

Latest news

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics